Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
LOS ANGELES (KABC) -- New technology that's allowing doctors to pinpoint prostate cancer long before it becomes a threat is now widely available. A former firefighter mentioned how this new imaging ...
What The 2024 NCCN Guidelines Say About... It does if a single state in the U.S. is any indication. In North Carolina, significantly higher rates of prostate cancer recurrence were reported among men ...
Among 134 men undergoing radical prostatectomy, PSMA PET accurately identified pathological tumor stage in 45% of patients compared with 28% of patients with MRI (P=0.003), reported Adam Kinnaird, MD, ...
PSMA PET scans significantly enhance detection and staging of prostate cancer, improving patient stratification and survival outcomes. Three FDA-approved PSMA PET scans are available, aiding in both ...
Study finds substantial concordance between PSMA-PET and conventional imaging for primary prostate cancer staging. Using prostate-specific membrane antigen positron emission tomography (PSMA-PET) for ...
Pretreatment 18F-PSMA-1007 PSMA PET/CT more accurately identifies prostate tumors compared with mpMRI. Fluorine-18 prostate-specific membrane antigen-1007 positron emission tomography/computed ...
Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...
PSMAddition is an international, open-label, prospective, phase 3 randomized controlled trial of 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC.
Liv Hospital integrates PET/CT diagnostics, radionuclide therapies and a multidisciplinary council to create individualized treatment plans for complex cancer and cardiac cases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results